Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

NCT02858206 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Neoplasms

Interventions

RADIATION: IMRT simultaneous integrated boost
DRUG: Nimotuzumab
DRUG: Paclitaxel
DRUG: Nedaplatin
PROCEDURE: Esophagectomy

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]